This mechanism contributes to maintaining genomic stability in cancer cells, thereby significantly reducing the efficacy of PARP inhibitors, increasing the risk of disease recurrence, limiting subsequent therapeutic options, and leading to a poorer prognosis. This evidence concerns the gene PARP1 and cancer.